\$92.3 B

INDIA BIOTECH HANDBOOK 2023

Vaccine


\$14B





Accelerating access to Cell & Gene Therapies

A pioneering clinical-stage cell and gene therapy company with end-to-end capabilities, on a mission to deliver transformational therapies affordably and bridge the access gap in India and globally.





India's first hospital-based Integrated and state-of-art Cell Therapy Development & Manufacturing facility



Multi-product facility designed to deliver global quality cell therapies



Disruptive and scalable manufacturing platforms to make cell therapies affordable and accessible



Leading India's access to CGT and poised to be the first to market CAR-T cell therapy in India



Innovating with a robust late-stage portfolio of next generation cell and gene therapies for global access

Reach us to discuss collaborations, investments and ideas that can change patients' lives.

Immuneel Therapeutics Pvt. Ltd.

*Source: Labiotech, Sep. 2022

Bengaluru, India



investors@immuneel.com



TABLE OF CONTENTS

Foreword by ABLE President	04
India Delegation #BI02023	06
Industry Co-leaders	09
Program Schedule	14
Overview of India's BioEconomy	18
India Pavilion Exhibitor Profiles	24
India Pavilion Exhibitor Positioning	38
Connect with Team India at BIO 2023	42
India Exhibits at BIO Boston 2023 Locator	48

ACKNOWLEDGEMENTS

India Biotech Handbook has been envisioned and published by Narayanan Suresh, Chief Operating Officer, Association of Biotechnology Led Enterprises (ABLE). Designed and printed by Sareeta Sajjan. The editorial responsibility, content, and analysis was co-ordinated and carried out by Srinivas Rao Chandan,

Senior Consultant to ABLE; Ms Pavana Praveen, Manager-BD0 & Ms Indrila Sengupta. Asst. Manager-BDO. Dr Balasubramanya S., General Manager is the Chief Coordinator for the INDIA Pavilion@BIO Boston, June 5-8, 2023.

Comments and questions are welcome and should be addressed to:

Narayanan Suresh, Chief Operating Officer, Email: coo@ableindia.org.in Website: www.ableindia.in

ASSOCIATION OF BIOTECHNOLOGY LED ENTERPRISES (ABLE)

No.123/C, 16th Main Road 4th Block, 5th Cross, Koramangala, Bangalore-560034, India. Tel.: +91-80-41636853





INDIA'S \$93 BILLION BIOECONOMY AIMS FOR INCREASED SELF-RELIANCE

G S Krishnan, Hon. President - ABLE

ABLE was formed 20 years ago by a small group of biotech industry leaders as they felt the need to articulate many niggling issues related to regulatory provisions and lack of a coherent policy for the segment. This happened when they visualized more entrepreneurs coming into the sector, providing by the wide range of products and services that can be developed using various biotechnological tools.

I can say confidently that ABLE, as an organization, has not looked back since the first steps taken by the visionary founders. It was evident during the Covid-19 pandemic years when ABLE members delivered more than 2.3 billion doses of vaccines not just for our own people but to the entire world in a very short span of time. Literally starting from scratch, our member companies produced enough and more testing kits for exports too. A wide range of anti-virals were produced to control the disease. Very few countries have showed such high levels of self-reliance in tackling the unexpected health disaster that swept the world for nearly three years from early 2020.

Of course, our member companies are not just relying on the past glory, they are preparing in every possible way to face the challenges of the future. They look to every available opportunity. As the world turns to alternate protein sources, Indian companies are at the forefront of developing a host of these products and is now a preferred destination for innovation, develop and manufacture the new age food products. As the world grapples with the problems induced by climate change, helped by innovative government policies, ABLE members played a key role in developing technologies for the conversion of Biomass into fuel and succeeded in the implementation of 10% blended ethanol in petrol. They will play even greater role as the nation sets up more bio refineries to produce enough biofuels to achieve the 20% blending target by 2025.

Some of India's key biotech companies and institutions are present @ BIO Boston 2023 to show case their capabilities for the world to see and seek collaborations to replicate these in other parts of the world.


This special publication, "India Biotech Handbook 2023", is an attempt to showcase these players who are present in this prestigious event. I am sure you will find this publication useful as you prepare to engage with India's \$93 billion and growing BioEconomy that has over 600 established companies and 7,300+ biotech startups.








AREAS OF INTEREST



www.curadev.in Contact: +91-120-4081818 Email: interact@curadev.in





DR RAJESH S GOKHALE

Secretary - Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India

Chairman - Biotechnology Industry Research Assistance Council (BIRAC)

r Rajesh S. Gokhale is the Secretary at Department of Biotechnology in the Ministry of Science & Technology, Government of India. He is presently on deputation from Indian Institute of Science Education & Research IISER Pune. Prior to this, he was at National Institute of Immunology NII and was also Director of CSIR-Institute of Genomics and Integrative Biology CSIR-IGIB for seven-and-half years. During his tenure he established the South Campus of CSIR-IGIB, where he led interdisciplinary initiatives in translational genomics research programs focused in delineating a variety of complex diseases.

Dr. Gokhale is trained as a chemical biologist from Indian Institute of Science IISc, Bangalore and Stanford University, USA. His significant research contributions are in discovering novel metabolites and their pathways, which dictate pathophysiology of human diseases. Recent work from his laboratory have identified two novel metabolites from infectious pathogen Mycobacterium tuberculosis, that are crucial for initiating complex infection process. His group have also significantly contributed to the understanding of autoimmune disease Vitiligo. Studies from his group has elucidated complex interplay between metabolic reprogramming and immune system, to develop novel therapeutic strategies that can tackle the underlying causes, rather than just the symptoms. Scientific work from his laboratory has been published in prestigious journals like Nature, Nature Chemical Biology, Molecular Cell, The Proceedings of the National Academy of Sciences etc. He has mentored more than 200 students and about 25 students have completed PhD thesis from his group. Dr Gokhale co-founded Vyome Biosciences Pvt. Ltd. VYOME in 2010, a biopharmaceutical company developing best in class drugs for dermatology. This company is presently completing Phase IIb clinical trial for drug-resistant acne and has launched OTC products in the market. Dr. Gokhale was a Wellcome Trust Senior Research Fellow, UK and an International HHMI Fellow, USA, He is recipient of several awards, including Infosys Prize, Shanti Swarup Bhatnagar Prize, National Bioscience Award, J C Bose National Fellowship and IIT Bombay Distinguished Alumni Award. He is also Fellow of all the three Indian National Science Academies.



NR ALKA SHARMA

Senior Advisor - Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India

Managing Director - Biotechnology Industry Research Assistance Council (BIRAC)

r. Alka Sharma is currently Scientist 'H'/Senior Adviser in the Department of Biotechnology DBT, Ministry of Science & Technology, Government of India.

Dealing with research and policy issues in the emerging areas of biotechnology, she has made significant contributions in med-tech innovation with national and international partnerships, early and late translational research on various domain specific areas of biotechnology such as vaccine research & development diagnostics, stem cells and regenerative medicine, biomedical engineering biodesign, setting up bioclusters across the country for innovation driven research, technology and product development. She has been instrumental in promoting and supporting public-private partnerships across the country and also in the commercialization of indigenous and affordable technologies for a large number of patients in urban and rural settings. Her efforts have resulted in the creation of several start-ups, the development of functional biomedical device prototypes, the transfer of technologies, and the creation of a pool of med-tech innovators in the country.

Actively involved in formulating various legislations in Biotech sector and heading the Biosafety Regulation Division including RCGM in DBT. She is the Coordinator for Management of COVID-19 related activities in DBT/ BIRAC and also contributing towards AtmaNirbhar Bharat through National Biotech Resource Indigenization Consortium (NBRIC). She is the Scientific Coordinator of four autonomous institutions of DBT and also coordinating for scientific activities of ICGEB. She is proactively promoting and supporting bilateral partnerships with various countries such as USA, Sweden, Finland, France and Australia. She has received training at the Department of Microbiology and Infectious Diseases, NIH, USA for the management of extramural programmes. Also she has also received "CSIR Technology Award for Innovation" for her translational work.



INDUSTRY CO-LEADERS

Dr. Sanjay Mishra

Senior Advisor Department of Biotechnology (DBT). Ministry of Science & Technology, Government of India

Dr. Manish Diwan

General Manager & Head, SPED Biotechnology Industry Research Assistance Council (BIRAC)

Dr. PKS Sarma

General Manager & Head, Technical, Biotechnology Industry Research Assistance Council (BIRAC)

Dr. Amita Joshi

Chief Manager, Technical Biotechnology Industry Research Assistance Council (BIRAC)

Dr. Aparna Sharma

Senior Manager, Technical Biotechnology Industry Research Assistance Council (BIRAC)

Dr. P M Murali

President, Council of Presidents, ABLE, CMD, Jananom

G S Krishnan

President, ABLE

Narayanan Suresh

COO, ABLE

Dr Balasubramanya S

General Manager, ABLE

Dr. Ramjee Pallela

COO, Atal Incubation Centre - Centre for Cellular and Molecular Biology (AIC-CCMB)

Ritika Marampalli

Head, Corporate Relations, Atal Incubation Centre - Centre for Cellular and Molecular Biology (AIC-CCMB)

Paul V. Thomas

Global Head, Portfolio Strateay & Program Management, Biocon Biologics Limited

Sushanth Boda

Senior Director - Strategy, BD & Innovation Biocon Biologics Limited

ALN Reddy

Vice President, Biological E. Limited

Dr. Martin Reers

Executive Vice President, Biological E. I imited

Dr. Selva Kumar Natesan

CEO, DSK InnoSciences Private Limited

Dr. Ananya Jeshtadi

VP - Global Business Development DSK InnoSciences Private Limited

Deepanwita Chattopadhyay

Chairman & CEO, IKP Knowledge Park



Bandhana Katoch

Principal Advisor, IKP Knowledae Park

Harshada Shrikant Wadkar

Senior Manager, IKP Knowledge Park

Dr. Tuhin Bhowmick

Cofounder & CEO, Pandorum Technologies

Vishal Goel

MD. Rx Propellant

Milind Ravi

CEO, Rx Propellant

Dr. Ketki Tulpule

VP - International Business Development & Strategy, Rx Propellant

Gaurav Kumar Rastogi

VP - Business Development, Rx Propellant

Poongumaran Panneer Selvam

MD, TICEL Bio Park Limited

Senthilkumar Vanarajan

Manager - (Scientific / Bioprocess) TICEL Bio Park Limited

Dr. Chandrashekaran Siddamadappa

MD, Chairman & Founder Vipragen Biosciences Private Limited

Yashas Chandrashekhar

COO, Vipragen Biosciences Private Limited

Dr. Narasimha Rao Nedunri

MD & CEO, Clonz Biotech Private Limited

INDIA BIOTECH HANDBOOK 2023 Pursuing Infinite Opportunities



Muralidhar Reddy Mamilla

COO, Clonz Biotech Private Limited

Vijay Babu Garlapalli

VP - Production, Clonz Biotech Private I imited

Aadya Malladi

Business Development Executive, Embio

Akash Murthy

Founder, Euprime

Murthy Chavali (CSN)

CEO, Satva Pharma Innovations Private Limited

Srikanth Konda

Director, Sparity, Inc.

Meghana Alluri

Client Success Specialist, Sparity, Inc.

BN Manohar

MD & CEO. Stempeutics Research Private Limited

Rippleben Bhavik Mehta

Investment Advisor Stempeutics Research Private Limited

Waman Wagh

MD. Adam Fabriwerk Pvt Ltd

Abishek lyer

Assistant General Manager Alembic Pharmaceuticals Limited

Manoj Gopalkrishnan

Founder & CEO, Algorithmic Biologics Pvt Ltd.

Sandeep Singh

MD, Alkem Labs

Hermes Vora

DGM - International Business Development, Ami Polymer Pvt Ltd

Rishi Ganju

Director - Marketing Atrimed Plant Science

Subir Dubey

VP - Business Development Aurigene Oncology Limited

Sujatha Rajagopalan

Associate Director -Business Development, Aurigene Oncology Limited

Akshay Shukla

Director, NBE Strategy & Business Development

Aurigene Pharmaceutical Services Limited

Dr. Ravikumar Gopalapillai

Scientist Bangalore Bioinnovation Centre (BBC)

Bharat B. Doshi

Founder & CEO BioDev Services Private Limited

Amit Vernekar

Founder Director Biosyl Technologies Pvt. Ltd.

Devang Pandya

AGM - International Business Development CBCC Global Research

Dr. Mohammad Atif Alam

Programme Lead (Technology Platforms -BD & Projects) Centre for Cellular and Molecular Platforms (C-CAMP)

Piyush Chahar

Director & Head - BD Chemveda Life Sciences Inc.

Manish Tandon

Chief Financial Officer Curadev Pharma

Rajesh Kumar

Associate Director, Forecasting & Analytics DelveInsight Business Research LLP

Aditya Nadimpalli

Head BD - Licensing, Strategic Partnerships, Alliance Management - India Dr. Reddy's Laboratories

Mayur Sangwai

Lead, Business Development Dr. Reddy's Laboratories

Venkata S Garimella

Vice President Intellectual Property Dr. Reddy's Laboratories

Dr. Himanshu Gadgil

CEO

Enzene Biosciences Limited

Dr. Satish Nagaraj

Head - Global Commercial Operations Enzene Biosciences Limited

Fherhard Raemisch

Head Business Development CMC & CDMO Еигоре Eurofins Advinus

Dr. Siyasankar Baalasubramanian

CEO & Co-Founder ImmunitasBio Private Limited

Mr. Sundeep Bambolkar

Jt. Managing Director Indoco Remedies I td

Ferran Garcia

VP Biosimilars B2B Intas Pharmaceuticals

Ansul Sinha

Assistant General Manager - Biosimilars Intas Pharmaceuticals

Nilendra Singh

Business Development Manager (EMEA USA AND APAC) JRF America

Jay Sheth

BD Head - US West & Canada Jubilant Biosvs

Dr. Ravichandran S

Senior Manager - Business Development Jubilant Biosys

Karan Bagaria

Kemwell Biophama Private Limited

Nagalakshmi Jeedimalla

Business Development Manager Laurus Labs

Anshuman Patwardhan

Senior Vice President, Business Development, Biotech, Lupin, Inc.

Atish Majumdar

President, Mankind Pharma Ltd

Dr. Ramesh Muthu

SVP - Global Business Development Mankind Pharma I td

Dr. Mohan Thiruvazhi

Business Consultant Mestastop Solutions Pvt. Ltd.

Saharsh Davuluri

Vice Chairman & MD Neuland Laboratories Ltd.

Dr. Prabuddha K Kundu

Co-founder & MD Premas Biotech Pvt I td

Dr. Nupur Mehrotra

Co-founder & COO Premas Biotech Pvt I td

Vivek Chandra

Head, Global Business Development Premas Biotech Pvt I td

Dr. Manoj Khera

Co-Founder 7 Director Presude Lifesciences Private Limited

Dr. Chirag Shah

Head Clinical Operations Raptim Research Limited





Neha Srivastava

Partner Remfry & Sagar

Pravin Shukla

Director Marketina & Business Develop-

Researchwire Knowledge Solutions Pvt. Ltd.

Parag Sancheti

CEO. Rubicon Research Pvt Ltd

Sagar Oak

VP Corporate development & Strategy Rubicon Research Pvt I td

Dr. Jugnu Jain

CEO, Sapien Biosciences

Dr. Somnath Sakore

Technical Director Seveillar Clinical Supplies Services Pvt Ltd

Sarat Patnaik

Head - Marketing Stelis Biopharma Pvt. Ltd.

Jaydeep Issrani

Senior General Manager - Business Development, Sun Pharma Advanced Research Company Ltd. (SPARC)

Rajesh Ranganathan

Vice President & Head, Corporate Development, Sun Pharma Advanced Research Company Ltd. (SPARC)

Manoj Thombare

Business Development and Licensina Sun Pharmaceutical Industries Ltd.

Rajesh Sinha

Dy General Manager Sun Pharmaceutical Industries Ltd.

Anjan Chakrabarti

VP & Head of Business Development for North America. Syngene International Limited

Dr. Sunit Maity

Sr. General Manager (Biologics Develop-Syngene International Limited

Dr. Sanjoy Mahanty

VP Head of Business Development - North America, TCG Lifesciences Private Limited

Esmail Samiwala

Sr. VP. Biologics USV Private Ltd

Ms. Shoba Shenoy

General Manager - Biologics Program USV Private Ltd

Siddharth Shah

Director - External Innovation - Asia Pacific Zoetis

Binu Philip

Sr. General Manager & Head, Business Development Zydus Lifesciences Ltd.

Mr. Jijo G. John

CEO, Calpine Group to India Delegaton #BIO 2023

Dr. D. Sudhakaran

General Manager Golden Jubilee Biotech Park for Women Society





PROGRAM SCHEDULE

BIO International Convention 2023

June 5-8 | Boston, MA, USA

India Pavilion Inauguration in Booth 3545 on June 5, 2023 | 12:30 PM by

DR. RAJESH S. GOKHALE

Secretary,

Department of Biotechnology (DBT)
Ministry of Science & Technology

Government of India



Scan the QR Code to access India Team Schedule



Scan the QR Code to access BIO Schedule





MEDICINAL CHEMISTRY SERVICES

Skanda offers integrated drug discovery solutions -Design, synthesis, hit to lead optimization for validated drug target. We have experienced team of chemist for process development / scale up and custom synthesis of drug intermediates, impurities and reference compounds.

DISCOVERY BIOLOGY

At Skanda Life Sciences, our Discovery biology division provides comprehensive services to accelerate drug discovery and development. We specialize in gene expression analysis, Western blot studies, cloning, and transfection focusing on Oncology, CNS, Osteoporosis, Pain and inflammation, metabolic disordes, etc.,

BIOANALYTICAL SERVICE

Skanda with state of art Bioanalytical facility complements chemistry and Discovery biology team for LCMS/MS method development, validation as well as quantification of analytes for permeability /ADME/Pharmacokinetics

ORPORATE OFFICE

#12, Sri Shaila Bramara, Nagarabavi, Bangalore -560091, India

PLATFORM TECHNOLOGIES

- · Luminescence, Fluorescence, Absorbance
- · FRET, TR-FRET, HTRF, Alpha screen
- Flow cytometry
- ELISA, Immunoblotting, IHC, ICC
- Microscopy
- PCR/RT-PCR
- · LCMS/MS, GCMS/MS, FTIR, NMR



+91-9663399155 +91-9538494265

P R&D CENTRE

Plot No. 67-P8, Phase II, Sector-II, KIADB Bidadi Industrial Area, Bidadi, Ramanagar 562109 India







FOCUS AREAS





through Advocacy











for the Biotech Sector





















AT THE PINNACLE OF IP EXCELLENCE

FOR

196 YEARS

YOUR VISION, OUR EXPERTISE.


GURUGRAM | CHENNAI | BENGALURU | MUMBAI

TRADEMARKS | PATENTS | COPYRIGHT | DESIGNS | IP LITIGATION PATENT LITIGATION | TECHNOLOGY MEDIA & TELECOM FASHION & LUXURY LAW | PLANT VARIETIES & BIODIVERSITY GEOGRAPHICAL INDICATIONS | CORPORATE LAW

www.remfry.com

INDIA TARGETS \$150 BILLION BIDECONDMY BY 2025

India's BioEconomy has crossed an estimated \$92 billion by value in the year 2022. The policy makers and industry together have now set an ambitious target of achieving a \$150 billion BioEconomy by 2025.



To achieve a \$150 billion BioEconomy is 2022, the contribution of each and some sectors need to nearly double in the next 2-3 years. This is possible because there are many new green shoots within the biotech segment that are showing signs of great performance. HERE'S HOW THE \$ 150 BILLION MAGIC WILL HAPPEN BY 2025:



BioPharma sector to grow to nearly \$68 billion from \$49 billion in 2022 (nearly 1.4 times). India made biosimilars are getting accepted in developed markets like the US and we can expect more nations to source cost effective biosimilars in many disease categories as these global quality medical products demonstrate their efficacy and popularity in foreign countries.



The Indian Diagnostics and medical devices market is likely to see a huge jump both in terms of consumption and exports. Covid-19 helped the nation to create the right ecosystem to manufacture, source, and export as well. The modern Diagnostics Labs services are spreading beyond big cities and towns. The "RT- PCR tests" done in small places are an indication of the spread of this expertise. India's BioEconomy from Diagnostics services and medical devices products is expected to touch \$30 billion by 2025.



Vaccines are expected to generate \$17 billion by 2025 and biotherapeutics are anticipated to add another \$20 billion by 2025. Recombinant and biosimilar products will be big contributors.



BioIndustrial is another important sector that has got fillip from the Prime Minister's vision of Atmanirbhar Bharat and India becoming "energy independent" by 2047. The Indian Government has approved the amendments to the National Policy on Biofuels and took decisions to increase biofuel production and advance the introduction of ethanol blended petrol with up to 20% blend from April 2023. The amendments include allowing more feedstocks for the production of biofuels. The Biofuels capacity in India is expected to grow from 5.2 billion liters in 2021 to 10.1 billion liters in 2025 (almost doubling). In terms of the economic value, the Biofuel will generate \$20 billion BioEconomy by 2025 from \$6 billion in 2021 (almost tripling).





BioAgri, consisting of Bt Cotton, pesticides, marine biotech, and animal biotech has the potential to nearly double its Bio-Economy contribution from \$10.5 billion to **\$20 billion** in 2025. The impetus on a circular economy will give the needed push to the sector.



The **BioServices** sector comprising CROs/ CDMOs and BioIT segment, is forecast to grow from \$6.4 billion to **\$26.6 billion**. The segment will nearly quadruple. Most of the large IT companies have dedicated biotech / health care practices.



Newer segments like smart proteins and peptide-based materials, **contact lens**, speech restorers, smart pills, nerve regenerators, portable dialysis, prosthetic limbs, new wave of smart telediagnostics will create a nearly **\$10** billion in BioEconomy.



"Alternate foods" or "smart proteins" is the preferred destination for both Innovation and manufacture in the Smart Protein area. There is a very big demand for fermentation capacities in this area from startups in the US. In the next three years, there is a potential for 10-million-liter fermentation-capacities to be set up in India. This will attract an investment of more than \$500 million which will generate a revenue of \$1 billion every year. These facilities could be located in strategic places which have all the infrastructure for setting these big fermentation faculties. The industry just needs the support from a regulatory and infrastructure point of view to capitalize on this great emerging opportunity.

GRANULARITY - BIDECONDMY

Segment	Value in \$billion							
	2015	2016	2017	2018	2019	2020	2021	2022
Biopharma	18.9	23.8	24.3	28.0	36.0	38.0	39.4	49.8
Bioagri	9.0	9.8	10.3	11.0	12.0	11.1	10.5	11.5
Bioindustrial	1.9	2.6	2.9	4.0	5.0	5.1	10.3	14.1
CRO/BioIT/ Research	5.3	5.5	7.0	8.0	9.5	10.5	5.4	9.3
Covid Economy	0.0	0.0	0.0	0.0	0.0	5.5	14.5	7.7
Total Bioeconomy	35.1	41.6	44.5	51.0	62.5	70.2	80.1	92.3*

YEAR 2030 FORECAST

India can leapfrog in the Vaccines and Therapeutics segment. These two together account for nearly 50 percent share of the BioPharma and the Diagnostics labs, medical devices, and services segment estimated to reach \$60 billion.



This is possible when the BioPharma sector races to hit the \$120-125 billion mark and each of the three segments—Agriculture including animal biotech and marine biotech,

Bioindustrial segment and the BioServices segment of Contract research, contract manufacturing, and, BioIT services cross the \$60 billion mark. It is possible if the Indian Government continues to take initiatives like it took during Covid and in shaping the Biofuels strategy.

In the BioPharma segment, India can leapfrog in the Vaccines and Therapeutics segment. These two together account for nearly 50 percent share of the BioPharma and the Diagnostics labs, medical devices, and services segment estimated to reach \$60 billion. The Biofuels segment is likely to contribute nearly \$50 billion in value, while enzymes will rake in \$20 billion. The BioServices segment is likely to touch \$50-60 billion or even more.



AVIDINVENT

Empowering Life Science Innovators

A specialized firm providing comprehensive intellectual property services for life sciences and chemical sciences. Maximize your innovations' protection and potential from conception to commercialization.

Patentability FTO Prior Art Bio sequences Plant Biotech Enzymes

Patent Drafting
Patent Filing
Prosecutions

Tech Landscape Competitive Intelligence



Dr. Puneeta Arora

Co-Founder, Registered Patent Agent – India Ex. Patent Liaison at DuPont, 14 years in IP PhD, Biotechnology-CCMB, Postdoc - UNC Chapel Hill



Ms. Sukriti Goyal

Co-Founder, Registered Patent Agent – India Ex. Patent Analyst at DuPont, 15 years in IP M.Sc. Biotechnology - IIT Mumbai, Master of Business Law - NLSUI



Dr. Becky Abraham
Senior Patent Associate
Ex. GE, Ex. Dow, Ex. Clariant, 10 years in IP
PhD, Postdoc, Biotechnology, Chemistry



Mr. P. Krishna Mohan Advisor & Mentor Global Director of Licensing at Dupont (Retd)



Dr. Santi Sudha SPatent Associate
PhD, Biochemistry









AIC-CCMB is a premier life-science incubator based in the Pharma Hub of India, Hyderabad. We offer 20,000 square feet of affordable lab and office space, as well as state-of-the-art equipment, scientific services, training, mentoring, and access to a network of professional advisors for entrepreneurs in the life-sciences and healthcare domains. By creating an incubator environment that fosters innovation and growth, AIC-CCMB helps these companies succeed and contribute to economic development in the community. The incubator is promoted by CCMB, a vibrant institute, engaged in molecular, structural, and genomic biology (http://CCMB.RES.IN). We are focused primarily on lead-stage and product-stage startups and support them by bringing in experts in regulatory, clinical, and marketing needs in addition to connecting them to investors.

Established with the support of the Atal Innovation Mission (AIM) of the National Institution for Transforming India (NITI Aayog), Government of India at CSIR — CCMB, we are dedicated to improving the quality of life for all. With a footprint in medtech, biopharma, animal health, and biodiversity conservation, we believe in industry-academia collaboration for One Health, One World.

www.aic.ccmb.res.in

aic@ccmb.res.in







Biocon Biologics is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to affordable biologics for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. BBL has acquired the global biosimilars business of its long-standing partner Viatris, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., EU, Australia, Canada, Japan. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, and other non-communicable diseases. It has many 'firsts' to its credit in the biosimilars industry. It has also signed a strategic alliance with Serum Institute Life Sciences for vaccines (subject to certain closing conditions) to address the inequitable access to lifesaving vaccines. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people and the planet to achieve key UN Sustainable Development Goals (SDGs).

www.biocon.com

info@biocon.com





Celebrating Life Every Day



Biological E. Limited (BioE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BioE develops, manufactures and supplies vaccines and therapeutics. BioE supplies its vaccines to over 140 countries and its therapeutic products are sold in India and the USA. BioE has regulatory approvals from US FDA / EMEA and other major regulatory agencies across the globe for its vaccines/biologics and injectable facilities.

In recent years, BioE has embarked on new initiatives for organizational expansion as a trusted CDMO partner, and is currently serving global clients as the largest and most advanced vaccine and biologics development and manufacturing hub. BioE offers a fully integrated service at a single site – a seamless solution that enables partners from clinical scale manufacturing, formulation development to commercial manufacturing. BioE employs cuttingedge technologies, experts, teams of scientists, to deliver high-quality vaccines and therapeutics using state-of-the-art facilities.

www.biologicale.com

info@biologicale.com





* BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL

Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit, Public Sector Enterprise, set up by Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India. BIRAC/DBT as a central enabler, nurtures biotech innovation ecosystem in the country to address unmet needs in Healthcare, Agritech, Industrial Biotech and Clean Environment. BIRAC acts at the industry-academia interface and implements its mandate through a wide range of impact initiatives that include providing risk capital through targeted funding, capacity building, common infrastructure creation, nucleating a network of strategic partnership with public private stakeholders, policy advocacy, data analysis and leads National Missions like Startup India and Make In India for Biotech Sector.

www.birac.nic.in

birac.dbt@nic.in







DSK INNOSCIENCES

DSK InnoSciences is a reputable Contract Research Organization for Chemistry with a decade of successful operation offering services to a wide range of global clients including pharmaceutical, veterinary, cosmetic, fragrance, polymer, electronic, and specialty chemical industries. DSK's operation is housed in a 30,000 sq. ft. building on five acres of land in Greater Bangalore, India.

While the Full Time Equivalent (FTE) model focuses on NCE synthesis, process development and impurities synthesis, the Fee for Service (FFS) model focuses on custom synthesis of building blocks, intermediates, reference compounds with delivery ranging from mg to MT. The company differentiates as a solution provider for even the most difficult chemistry problems with a track record of 98% projects leading to successful completion.

The company is proud of their strong commitment to employee welfare, QMS, safety, environmental sustainability, green energy, and social responsibility activities.

dskinnosciences.com

info@dskinnosciences.com



KP KNOWLEDGE PARK

IKP Knowledge Park is a research park and incubator in Hyderabad and Bangalore, India, with the mission to advance deeptech and co-create solutions for tomorrow in health and plant systems. We build innovation ecosystems.

IKP provides land, lab space, technology, incubation, advisory services, and seed stage funding to innovative companies in biopharma, medtech, agri-food, and sustainability. Our footprint spreads across India, with around 1500 innovations supported in 90+ cities and towns in the country. This includes innovation projects, startups, SMEs, and large companies from India, as well as MNCs from the USA, Germany, Japan, South Korea, and Israel.

We are at BIO to discuss opportunities for

- >> Tech transfer from our portfolio of some amazing innovations
- Your presence in our 200-acre campus in Genome Valley, Hyderabad, or at IKP Bangalore
- ▶ Partnership for IKP ONE PRIZE, a set of unique Global Grand Challenges in One Health, Biodiversity and Conservation
- Cross-border collaboration

www.ikpknowledgepark.com

info@ikpknowledgepark.com











KARNATAKA INNOVATION AND TECHNOLOGY SOCIETY

Karnataka Innovation and Technology Society (KITS) functioning under brand "K-tech" administers incentives and concessions to Startups, IT, BT, ESDM and AVGC companies and is also made single point stop for providing all information that facilitates the establishment of above industries in the State.

Karnataka has been at the forefront of biotechnology in India and is rightly known as the Biotech Capital of India. The Karnataka Millennium Biotechnology Policy of 2001 was the first dedicated biotechnology promotion and development of Biotech Industry policy in the country. Department has set up various academic institutes of high repute, innovation hubs and skill development centres across the state to strengthen the biotech ecosystem and has supported 173+Biotech/Agritech/Medtech Startups under Elevate Idea2PoC progam. The bioeconomy of Karnataka is currently valued at ~USD 24.4 billion contributing 33% of the national share and presently hosts about 60% of the bio-tech companies in India and employs about 54% of the country's total bio-tech workforce.

kitsgok@karnataka.gov.in

kitsgok@karnataka.gov.in









KERALA STATE INDUSTRIAL DEVELOPMENT CORPORATION

Kerala State Industrial Development Corporation (KSIDC) is the premier agency of the Government of Kerala, mandated to for industrial and investment promotion in Kerala. Formed in 1961, KSIDC's primary objective was to promote, facilitate and finance large and medium-scale industries and catalyze the development of physical and social infrastructure required for industrial growth in the state. The one-stop-shop for any investment in Kerala, KSIDC offers a comprehensive set of services that an investor needs to set up an enterprise in the State. A nodal agency for foreign and domestic investments in Kerala, KSIDC facilitates clearances, and approvals, and processes various incentive schemes for starting new business ventures. KSIDC acts as a spokesman for the State spreading its industrial ethos besides being an interface between the Government and the Industry. KSIDC team includes a core group of skilled professionals from various fields like Engineering, Management, Finance, and Law.

www.ksidc.org

www.ksidc.org







PANDORUM TECNOLOGIES

Pandorum is a biotechnology company working in the fields of Tissue Engineering and Regenerative Medicine, based out of India (Bangalore) and the US (MBC BioLabs, Bay Area). Pandorum uses its proprietary technology platform to develop advanced therapeutics for regenerative reprogramming of human tissues. Pandorum's technology platform and products are protected by a portfolio of 11 IP families. Pandorum's flagship product, Kuragenx- the 'Liquid' cornea, has demonstrated remarkable vision restoration in New Zealand rabbits suffering from ulcerative corneal blindness with severe inflammation and fibrosis. Kuragenx has been assigned by USFDA to the Office of Tissues and Advanced Therapies, and our First in Human clinical study is planned for 2024 to treat advanced keratitis – a severe indication with unmet medical needs.

Pandorum has been supported by a number of Government grants and awards and has raised \$15 million so far, from prominent billionaire industrialists and VCs including Binny Bansal, T K Kurien, Sunil Munjal, Indian Angel Network (IAN) and 500 Startups. Pandorum has tied up with Northwestern University, Feinberg School of Medicine (Chicago, US) as its clinical study partner.

www.pandorum.com

contact@pandorumtechnologies.in







Rx Propellant is India's leading life science infrastructure platform, building capacities for research and manufacturing. The platform has a portfolio of 6.5 million square feet spanning nine projects in prominent life science clusters in Bengaluru, Hyderabad (Genome Valley) and Mumbai.

We offer tenant-configurable Lab Spaces for R&D and built-to-suit Flexi Factories for manufacturing that enable organizations to establish and expand their operations in India while staying asset-light. The team brings a unique blend of domain expertise in life science and a deep understanding of the infrastructure needs of the industry. Synergizing with infrastructure, Rx Propellant also provides ecosystem services to ensure tenant success through initiatives such as access to scientific networks, talent-skilling, and support for growth-stage companies.

www.rxpropellant.com

info@rxpropellant.com







TICEL Biopark Limited, Chennai, Tamil Nadu, India, is a state-of-the-art biotechnology park established in 2004 in Tamil Nadu, India. TICEL Biopark is promoted by TIDCO (Tamil Nadu Industrial Development Corporation) in technical collaboration with Cornell University, USA. TICEL Biopark supports the biotech ecosystem from the early stages of research to pilot-scale production by providing laboratory infrastructure and equipment support. Major companies such as Biocon Biologics, Teva Pharma, Levim Biotech, and PerkinElmer are located in Ticel Bio Park.

TICEL provides laboratory infrastructure that supports the creation of GMP/GLP/ Contract Research (CRO) / Contract Manufacturing (CMO) / testing facility. TICEL infrastructure includes utilities such as an RO water plant, Gas Bank, Vacuum air, Compressed air, Fume hood exhaust with scrubber, HVAC system, Bio waste disposal, and an STP and ETP plant.

Other facilities

- Biotech Core Instrumentation Facility
- >> Clean room facility for the production of biopharmaceutical
- ▶ Bio-Incubation Centre

www.ticelbiopark.com

marketing@ticelbiopark.com







Vipragen Biosciences Pvt. Ltd. is a CRO certified by NGCMA for OECD-GLP to carry out safety studies for regulatory submissions. The laboratory has been certified by AAALAC, NABL, and DCGI to support drug discovery and development. Vipragen has deep scientific and research knowledge in areas such as General Toxicology, Reproductive Toxicology, Genetic Toxicology, Pharmacology, Analytical Chemistry, Bioanalytical and ADME.

Located in the heritage city of Mysore, Vipragen has been serving companies worldwide for over a decade. We serve clients with diverse research requirements and assist them in advancing their product portfolio with reliable data, compliant with global quality standards. The robust platform technology development programmes at Vipragen enable collaborations with global partners to bring innovative solutions to create a safer tomorrow.

www.vipragen.com

bd@vipragen.com





CSIR - Central Drug Research Institute, Lucknow Council of Scientific and Industrial Research Ministry of Science & Technology, Govt. of India



A Centre for Integrated Drug Discovery and Development

CSIR-CDRI is a premier biomedical research institute focused on fundamental research, discovery and development of drugs, novel process technologies and diagnostics. Areas of focus are Infectious diseases, Endocrine and Metabolic disorders, Neurodegenerative disorders, Cancer and Reproductive health. The Institute has a proven track record of developing novel chemical entities all the way to market.

Products in Market











Oral Contraceptive

Antimalarial drug

Memory Enhancer

Fracture healing & Ost osteoporosis management

Drug Pipeline (Small Molecule)

Can	didate Drug / Lead Compound	Indication	Lead Optimization	IND Enabling studies	IND Filed	Phase I	Phase II	Phase III
S-007	-1500 (Licensed)	Fracture healing						
L-Orm	neloxifene (Licensed)	Female contraceptive						
S-011-	-1793	Malaria						
SB-C	DRI4-105	Neuropathic pain						
S-016	-1348	Colon cancer						
S-016	-1271	Complicated UTI						
S-017	-622	Hyperlipidemia						

Major Facilities

- GLP Test facility for pharmaceuticals
- Clinical formulation manufacturing facility
- National Laboratory Animal Facility
- Sophisticated Analytical Instrument Facility
- NABL accredited Phase I Trial Centre
- Drug Testing Laboratory

Business Model

- Co-development
- Out-licensing
- Contract R&D
- Consultancy

For business queries, please contact Head, Business Development on head.bdu@cdri.res.in

Ocsir cdri
Ocsir.cdri
www.cdri.res.in

INDIA PAVILION EXHIBITOR POSITIONING





StandOUT Zone 3545 - IP13

Clonz Biotech
Embio
Euprime
Radiant Research
Satya Pharma Innovations
Skanda Life Sciences
Sparity, Inc.
Stempeutics Research

RxPropellant 3545 - IP5

TICEL 3545 - IP4

Biocon Biologics 3545 - IP6 Pandorum 3545 - IP7



400 sq. ft.



200 sq. ft.



100 sq. ft.



50 sq. ft.



INDIA PAVILION EXHIBITOR POSITIONING



KSIDC 3545 - IP3	KITS, 3545 -	IKP Knowledge Park 3545 - IP1	
BIRAC 3545 - IP8	Vipragen 3545 - IP9	Biological E 3545 - IP10	DSK Innosciences 3545 - IP11 AIC-CCMB 3545 - IP12





























BIOTECH POLICY 2022-27

₹200 Cr. @25% Capital Subsidy

@15%
Operational Subsidy

7 100 Cl 007% Interest Subsidy a lot more





Gujarat State Biotechnology Mission

Nodal Biotechnology facilitation unit of provincial government of Gujarat, with a funding of \approx INR 60 cr, and other peripheral funds and infrastructure development



Savli Technology & Business Incubator

Dedicated space for innovators, ideators and start-ups, in the heartland of education: Vadodara. The incubator has State-of-the-Art Laboratory Infrastructure and Business Acceleration facilities



Gujarat Biotechnology Research Centre

A research facility dedicated to harnessing the potential of biotechnology, to address local and global challenges



Gujarat Biotechnology University

An university grounded in the principle of learning by doing, has been established in collaboration with University of Edinburgh. The university tenders post graduation through research, in 5 different disciplines of biotechnology.

Experience the Dynamic Biotech Landscape of Gujarat, Where Breakthroughs and Opportunities Await....

Join Us on the Path of Excellence and Progress!

for more details visit - https://btm.gujarat.gov.in/




Sl no.	Organization	Contact Person
1	Association of Biotechnology Led Enterprises (ABLE)	Dr. Balasubramanya S
2	Atal Incubation Centre - Centre for Cellular and Molecular Biology (AIC-CCMB)	Dr. Ramjee Pallela
3	Biocon Biologics Limited	Mr. Paul V. Thomas
4	Biological E. Limited	Mr. ALN Reddy
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Biotechnology Industry Research Assistance Council (BIRAC)	Dr. Manish Diwan
6	DSK InnoSciences	Dr. Selva Kumar Natesan
7	IKP Knowledge Park	Ms. Deepanwita Chattopadhyay
8	Pandorum Technologies	Dr. Tuhin Bhowmick
9	Rx Propellant	Mr. Vishal Goel
10	TICEL Bio Park Limited	Mr. Poongumaran Panneer Selvam
11	Vipragen Biosciences	Dr. Chandrashekaran Siddamadapp
12	Clonz Biotech	Dr. Narasimha Rao Nedunri
13	Embio Limited	Mr. Aadya Malladi
14	Euprime	Mr. Akash Murthy
15	Radiant Research Services	Dr. Ashok Godavarthi
16	Satya Pharma Innovations	Mr. Murthy Chavali (CSN)
17	Skanda Life Sciences	Dr. Yogisha. S.
18	Sparity, Inc.	Mr. Srikanth Konda
19	Stempeutics Research	Mr. BN Manohar
20	Adam Fabriwerk	Mr. Waman Wagh
21	Alembic Pharmaceuticals	Mr. Abishek lyer
22	Algorithmic Biologics	Mr. Manoj Gopalkrishnan
23	Alkem Labs	Mr. Sandeep Singh
24	Ami Polymer Pvt Ltd	Mr. Hermes Vora
25	Atrimed Plant Science	Mr. Rishi Ganju
26	Aurigene Oncology Limited	Mr. Subir Dubey
27	Aurigene Pharmaceutical Services	Mr. Akshay Shukla
28	Bangalore Bioinnovation Centre (BBC)	Dr. Ravikumar Gopalapillai
29	BioDev Services Private Limited	Mr. Bharat B. Doshi
30	Biosyl Technologies Pvt. Ltd.	Mr. Amit Vernekar
31	CBCC Global Research	Mr. Devang Pandya
32	Centre for Cellular and Molecular Platforms (C-CAMP)	Mr. Mohammad Atif Alam
33	Chemveda Life Sciences Inc.	Mr. Piyush Chahar
34	Curadev Pharma	Mr. Manish Tandon



Email ID	Website
gm@ableindia.org.in	www.ableindia.in
ramjee@ccmb.res.in	https://aic.ccmb.res.in/
paul.thomas@biocon.com	www.biocon.com
Reddy.ALN@biologicale.com	www.biologicale.com
sped@birac.nic.in	www.birac.nic.in
selvakumar.n@dskinnosciences.com	www.dskinnosciences.com
deepanwita@ikpknowledgepark.com	www.ikpknowledgepark.com
tuhin@pandorumtechnologies.in	www.pandorum.com
vishal.goel@rxpropellant.com	www.rxpropellant.com
md@ticelbiopark.com	www.ticelbiopark.com
chandra@vipragen.com	www.vipragen.com
ceo@clonzbio.com	www.clonzbio.com
aadya@embio.co.in	www.embio.co.in
akash@euprime.org	www.euprime.org
ashok@radiantresearch.in	www.radiantresearch.in
murthycsn@satyarx.com	www.satyarx.com
yogisha.s@skandalifesciences.com	www.skandalifesciences.com
srikanth@sparity.com	www.sparity.com
manohar@stempeutics.com	www.stempeutics.com
waman.wagh@adamfabriwerk.com	www.adamfabriwerk.com
abishek.iyer@alembic.co.in	www.alembicpharmaceuticals.com
manoj@algorithmicbiologics.com	www.algorithmicbiologics.com
sandeepsingh@alkem.com	www.alkemlabs.com
hermes.v@amipolymer.com	www.amipolymer.com
info@atrimed.com	www.atrimed.com
subir_d@aurigene.com	www.aurigene.com
akshays@aurigeneservices.com	www.aurigeneservices.com
info@bioinnovationcentre.com	www.bioinnovationcentre.com
bharat.doshi@biodevservices.com	www.biodevservices.com
amitverk@gmail.com	www.biosyltech.com
devang.pandya@cbcc.global	www.cbcc.global
atifm@ccamp.res.in	www.ccamp.res.in
piyush.chahar@chemvedals.com	www.chemvedals.com
manish@curadev.in	www.curadev.in





FOUNTET WITH TEAM TUNTA AT RTD 2022

CULI	35	DelveInsight Business Research LLP	Mr. Rajesh Kumar
<u> </u>	36	Dr. Reddy's Laboratories	Mr. Aditya Nadimpalli
_	37	Enzene Biosciences Limited	Dr. Himanshu Gadgil
	38	Eurofins Advinus	Mr. Eberhard Raemisch
	39	HiMedia Laboratories Private Limited	Mr. Vishal Warkhe
1	40	ImmunitasBio Private Limited	Mr. Sivasankar Baalasubramanian
I	41	Indoco Remedies Ltd	Mr. Sundeep Bambolkar
I	42	Intas Pharmaceuticals	Mr. Ferran Garcia
ICAM INDIA	43	Jananom Private Limited	Dr. P.M. Murali
_	44	Jubilant Biosys	Mr. Jay Sheth
	45	Kemwell Biopharma Private Limited	Mr. Karan Bagaria
	46	Laurus Labs	Ms. Nagalakshmi Jeedimalla
	47	Lupin, Inc.	Mr. Anshuman Patwardhan
	48	Mankind Pharma Ltd	Mr. Ramesh Muthu
_	49	Mestastop Solutions Pvt. Ltd.	Dr. Mohan Thiruvazhi
=	50	Neuland Laboratories Ltd.	Mr. Saharsh Davuluri
	51	Premas Biotech Pvt Ltd	Dr. Prabuddha K Kundu
	52	Presude Lifesciences Private Limited	Dr. Manoj Khera
_	53	Raptim Research Limited	Dr. Chirag Shah
<u>-</u>	54	Remfry & Sagar	Ms. Neha Srivastava
CONNEC	55	Researchwire Knowledge Solutions Pvt. Ltd.	Mr. Pravin Shukla
5	56	Rubicon Research Pvt Ltd	Mr. Parag Sancheti
	57	Sapien Biosciences	Dr. Jugnu Jain
	58	Seveillar Clinical Supplies Services Pvt Ltd	Dr. Somnath Sakore
	59	Stelis Biopharma Pvt. Ltd.	Mr. Sarat Patnaik
	60	Sun Pharma Advanced Research Company (SPARC)	Mr. Jaydeep Issrani
	61	Sun Pharmaceutical Industries Ltd.	Mr. Manoj Thombare
	62	Syngene International Limited	Dr. Sunit Maity
	63	TCG Lifesciences Private Limited	Dr. Sanjoy Mahanty
	65	USV Private Ltd	Mr. Esmail Samiwala
	66	Zydus Lifesciences Ltd.	Mr. Binu Philip
	67	Calpine Group	Mr. Jijo G. John
	68	Devsynthesis India Private Limited	Mr. Ashutosh Pathak
	69	LEX IP Care	Mr. Calab Gabriel D.
	70	Pharmadesk Solutions Private limited	Dr. Ravindra Bhavsar
	71	P S Davar and Company	Mr. Praneed Singh Davar
	72	Golden Jubilee Biotech Park for Women Society	Dr. D. Sudhakaran
(/. /.	NDIA BIOTECH ANDROOK 2023 Pursuing Infinite Infinite Proportunities	





info@delveinsight.com	www.delveinsight.com
anadimpalli@drreddys.com	www.drreddys-cps.com
bd@enzene.com	www.enzene.com
info@advinus.com	www.advinus.com
vwarkhe@himedialabs.in	www.himedialabs.com
shiv@immunitasbio.com	www.immunitasbio.com
svb@indoco.com	www.indoco.com
fgarcia@intaspharma.com	www.intaspharma.com
pmmurali@jananom.com	www.jananom.com
jay.sheth@jubilantbiosys.com	www.jubilantbiosys.com
karan.bagaria@kemwellpharma.co	https://www.kemwellbiopharma.com/
bdsynthesis@lauruslabs.com	www.laurussynthesis.com
anshumanpatwardhan@lupin.com	www.lupinworld.com
rameshm@mankindpharma.com	www.mankindpharma.com
mohan@mestastop.com	www.mestastop.com
saharsh@neulandlabs.com	www.neulandlabs.com
contact@premasbiotech.com	www.premasbiotech.com
manoj.khera@presude.com	www.presude.com
chirag.shah@raptimresearch.com	www.raptimresearch.com
neha.srivastava@remfry.com	www.remfry.com
pravin.shukla@researchwire.in	www.researchwire.in
parag@rubicon.co.in	www.rubicon.co.in
queries@sapienbio.com	www.sapienbio.co.in
somnath.sakore@seveillar.com	www.seveillar.com
sarat.pat@gmail.com	www.stelis.com
jaydeep.issrani@sparcmail.com	www.sparc.life
manoj.thombare@sunpharma.com	www.sunpharma.com
sunit.maity@syngeneintl.com	www.syngeneintl.com
sanjoy.mahanty@tcgls.com	www.tcgls.com
biologics@usv.in	www.usvindia.com
binuphilip@zyduslife.com	www.zyduslife.com
jijo@calpinetech.com	www.calpinetech.com
ashu20022@gmail.com	www.dev-synthesis.com
calab@lexipcare.com	www.lexipcare.com
ravindra.b@pharmadesk.com	www.pharmadesk.com
psdavar@psdavar.co.in	www.psdavar.com
gm@biotechpark.co.in	www.biotechpark.co.in









ARTDSIGNZ

Expression of perspectives Impressions to communicate.

Visual creatives - Digital art for Bioscience and Life science.





We create through the universal language of visual medium with Concept Art,

Illustrations & Digital Graphics supported by 3D prototyping & inclusive art-creatives to a specific need, brief or objective.

Communicate Ideas, Process, Products or Services through visuals.

Innovation, Research, Branding and more.


We co-create as resource or in collaboration as option for Startups, Business, Corporates, Institutions, Academia in Visual designs.





SOI Design and Crest LLP www.soidna.in sandhyaksirsi@soidna.in

Launching NFT, online and creatives library





India Exhibitors

India Pavilion Exhibitors

Sl no	Exhibtitor	Booth no.
1	Ami Polymer Pvt Ltd	1885
2	Aurigene Pharmaceutical Services Limited	3443
3	CBCC Global Research	2666
4	HiMedia Labs	3187
5	Kemwell Biopharma Private Ltd.	585
6	Premas Biotech	2945
7	Stelis Biopharma	2676
8	Syngene International Limited	265

Sl no	Exhibtitor	Booth no.
1	Association of Biotechnology Led Enterprises (ABLE)	3545
2	IKP Knowledge Park	3545 - IP1
3	Karnataka Innovation & Technology Society, Govt. of Karnataka	3545 - IP2
4	Kerala State Industrial Development Corporation (KSIDC)	3545 - IP3
5	TICEL Bio Park Limited	3545 - IP4
6	Rx Propellant	3545 - IP5
7	Biocon Biologics Limited	3545 - IP6
8	Pandorum Technologies	3545 - IP7
9	Biotechnology Industry Research Assistance Council (BIRAC)	3545 - IP8
10	Vipragen Biosciences Private Limited	3545 - IP9
11	Biological E. Limited	3545 - IP10
12	DSK InnoSciences Private Limited	3545 - IP11
13	Atal Incubation Centre - Centre for Cellular and Molecular Biology	3545 - IP12
14	Clonz Biotech Private Limited	Stand0UT
15	Embio Limited	Zone 3545 - IP13
16	Euprime	3343 - IF IS
17	Radiant Research Services Pvt. Ltd.	
18	Satya Pharma Innovations Private Limited	
19	Skanda Life Sciences	
20	Sparity, Inc.	
21	Stempeutics Research Private Limited	





ASSOCIATION OF BIOTECHNOLOGY LED ENTERPRISES

Association of Biotechnology Led Enterprises - ABLE is a not-for-profit pan-India forum that represents the Indian Biotechnology Sector. It was launched in April 2003, after industry leaders felt a need to form an exclusive forum to represent the Indian Biotechnology Sector.

ABLE has over 400 members from all across India representing all verticals of the sector like Agribiotech, Bio-pharma, Industrial biotech, Bioinformatics, Investment banks and Venture Capital firms, leading Research and Academic Institutes and Law Firms and Equipment Suppliers.

The primary focus of ABLE is to accelerate the pace of growth of the Biotechnology sector in India, through partnering with the Government in their biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaboration and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector.

ABLE Council of Presidents, that comprises of all past presidents of the organization, has been set up to provide impetus to the growth of the Biotech business ecosystem to leverage their multi-sectoral expertise. ABLE thus catalyses a symbiotic interface between the industry, the government, academic and research institutes and domestic and international investors.

www.ableindia.in

info@ableindia.org.in













BIRAC - An Ecosystem Enabler

Funding and Beyond

Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit section 8, Schedule B, Public Sector Enterprise, set up by Department of Biotechnology (DBT), Government of India as an Industry-Academia Interface Agency to strengthen and empower the emerging Biotech enterprise to undertake strategic research and innovation, addressing high unment needs through development of affordable products and technologic



BIRAC's Impact

Nurturing & Strengthening Biotech Innovation Ecosystem












- Internationally acclaimed OECD GLP & USFDA audited Preclinical CRO
- State-of-the-art infrastructure spread across 250,000 sq.ft. area
- AAALAC accredited & OLAW approved large vivarium with 90 experiment rooms conforming to international standards
- 14+ years of contract research experience, 16000+ GLP studies submitted globally
- Conformance to Global Regulatory Norms (USFDA, EMEA, Health Canada, WHO, MHRA, ANVISA, DCGI, RCGM)
- Vast experience of handling Small Molecules, NCEs, Peptides, Biologics, Biosimilars, Vaccines, Nuturaceuticals, Medical Devices, Cosmetics, etc.
- Best in industry team leads & talent pool with extensive industry experience & domain expertise



SERVICES FOR PHARMA



Guidelines: ICH, OECD, EMEA-CHMP, US-FDA, SCHEDULE Y





bioneeds@bioneeds.in

